#Canada #Hamilton #Hamilton Ontario #AtomVie Global #radiopharmaceuticals

AtomVie Global Radiopharma's Grand Opening in Hamilton

On September 4, 2026, AtomVie Global Radiopharma (AtomVie), a prominent player in the radiopharmaceutical industry, proudly inaugurated its newly constructed, high-tech manufacturing facility located at 10 Aeropark Boulevard, Hamilton, Ontario. This event signifies a major step in AtomVie’s mission to provide life-changing precision therapies to patients worldwide and reflects a crucial evolution in their operational capabilities.

The new facility represents a remarkable investment of over $160 million and spans 72,300 square feet, making it the largest single-site contract development and manufacturing organization (CDMO) space for radiopharmaceuticals in North America. It boasts both low-to-high throughput production capabilities, which result in a tenfold increase in AtomVie’s manufacturing capacity, allowing for an unmatched progression from early drug development to commercial production.

As a specialized facility designed for lifecycle growth, AtomVie’s new site features custom spaces tailored for the distinct requirements of their clients as they develop and scale their operations. This facility is not just a significant addition to AtomVie’s infrastructure but also an emblematic achievement for Canadian innovation in nuclear medicine, allowing them to continue their commitment to delivering high-quality radiopharmaceuticals.

A Legacy of Expertise

AtomVie has its roots as a spinout from the Centre for Probe Development and Commercialization (CPDC), which is affiliated with McMaster University. This esteemed Centre has been pivotal in advancing Canada’s expertise in radiopharmaceutical innovation and manufacturing. Since its inception, AtomVie has consistently built upon a decade of experience, having successfully supported over 70 clinical development and technology transfer programs while producing more than 1,000 compliant Good Manufacturing Practices (cGMP) batches. The organization has provided over 4,400 cGMP doses to patients across 28 countries and six continents, maintaining an impressive delivery success rate of over 99%.

The leadership team at AtomVie envisions a future filled with growth and expanded capabilities. Bruno Paquin, Chief Executive Officer of AtomVie, emphasized that the Grand Opening is a landmark moment, stating, "This new purpose-built facility enhances our reliable global delivery and scientific expertise. It enables us to support the development and commercialization of our partners' pipelines, fundamentally transforming patients' lives by ensuring the availability of high-quality radiopharmaceuticals."

Kevin McNeill, the Chairman of AtomVie’s Board of Directors, echoed these sentiments, noting that the facility’s launch exemplifies the team’s dedication along with the trust placed in them by partners and clients.

A Celebration of Partnerships

The Grand Opening event attracted various stakeholders, including government officials, clients, partners, and members of the wider radiopharmaceutical community. Attendees had the opportunity to tour the facility and witness firsthand how AtomVie’s expertise is paving the way for the next generation of precision cancer therapies. This collaborative spirit underscores AtomVie’s commitment to transparent partnerships and shared success with stakeholders in this critical field.

As AtomVie continues to expand its reach and operational capabilities, the new facility stands as a testament to the promising future of radiopharmaceutical manufacturing. With its aim to employ over 200 professionals by the end of 2026, AtomVie is well-positioned to lead the charge in developing groundbreaking therapies that can change lives around the globe. For more information about AtomVie and its services, visit AtomVie’s official website.

This event is not just a celebration of AtomVie’s growth; it marks a step forward for the entire radiopharmaceutical industry, showcasing the potential embedded in innovation and collaboration. The future of nuclear medicine looks promising with AtomVie at the forefront.